Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | N Rudra-Ganguly, C Lowe, C Virata, M Leavitt, L Jin, B Mendelsohn, J Snyder, H Aviña, C Zhang, DL Russell, M Mattie, PYang, B Randhawa, G Liu, F Malik, M Vest, JD Abad, CC Kemball, R Hubert, S Karki, B Anand, Z An, J Grant, JE Dick, F Doñate et. al. | ||||||||||||
Title | AGS62P1, a Novel Anti-FLT3 Antibody Drug Conjugate, Employing Site Specific Conjugation, Demonstrates Preclinical Anti-Tumor Efficacy in AML Tumor and Patient Derived Xenografts | ||||||||||||
|
|||||||||||||
URL | http://www.bloodjournal.org/content/126/23/3806?sso-checked=true | ||||||||||||
Abstract Text | Blood 2015 126(23):3806 |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AGS62P1 | FLT3 Antibody 5 | AGS62P1 is a human anti-FLT3 antibody in conjugation with a microtubule disrupting agent, which may have anti-tumor activity (Blood 2015 126(23):3806, PMID: 29757653). |
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FLT3 positive | acute myeloid leukemia | predicted - sensitive | AGS62P1 | Preclinical - Patient cell culture | Actionable | In a preclinical study, AGS62P1 inhibited growth of FLT3-positive acute myeloid leukemia cell lines in culture, and led to tumor growth inhibition and regression in patient-derived xenograft (PDX) models (Blood 2015 126(23):3806). | detail... |